Open in interactive viewer → charts, metric popovers & call review

Journey Medical's 25-Million-Life Formulary Win Lands on a Stock Down 36%

Emrosi crossed $9M in quarterly sales and a second positive-EBITDA quarter — but the equity has been cut by a third into the print, and guidance is deferred again
FBIO · Earnings Call · 2026-11-12

The formulary that pays

This report sits on Fortress Biotech's ticker, but the transcript is Journey Medical's — the dermatology commercial engine whose net product sales have quietly become the whole story. For several quarters the Emrosi rosacea launch has been told through prescription counts and prescriber breadth; this quarter it finally got a dollar-shaped catalyst. Emrosi did “$9 million in the third quarter, up year-over-year and sequentially from the second quarter” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12, and total revenue reached $19 million, up from $15 million a year ago. More importantly, management says the company delivered positive EBITDA for a second straight quarter — the first time the launch math has crossed from "volume story" to "self-funding story." But the real news is reimbursement. On the call, COO Ramsey Alloush flagged a large national plan win that becomes effective January 2027. CEO Claude Maraoui put a number on it: “This is a plan with over 25 million lives.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 That matters because Emrosi's economics have been trapped behind the copay bridging program — a workaround for scripts that can't clear formulary. As Maraoui described, the company is betting on conversion: “there is a lot of progress and a lot of momentum that's being built” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 around negotiations with national formulary plans. Turning unreimbursed scripts into reimbursed, rebatable ones is the single biggest lever on gross-to-net and therefore on revenue per script. Context matters here: a year ago Alloush was framing the opportunity as “38% quality of the 192 million lives having access to Emrosi with a single step therapy or better” — Ramsey Alloush, Chief Operating Officer and General Counsel · 2026-08-12, and management has repeatedly promised the shift away from coupons would come with wins like this. So the formulary win is a kept promise, not a fresh claim — but it is the first one large enough to visibly bend the revenue line.

The catch: October and the copay treadmill

Here is where the narrative frays. Analysts pressed on October script data running below the third-quarter weekly average. Maraoui's answer was candid and revealing: each time the company resets the copay — launched at $0.50, moved to $0.0, then $0.35 in January, now back to $0.50 — demand wobbles. “there is a little bit of a downturn, it might take anywhere from 4 to 8 weeks and then you start seeing the charge back up” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12 is a pattern, not an accident: the patient mix walking through the door is dictated by coverage timing and deductible resets, not by the sales force. That is the tension worth holding onto. The company has built an impressive field operation — sales reps expanded from 35 to roughly 40, and management floated another 2027 headcount increase — but the throttle on near-term revenue is still payer mechanics, and the first quarter of a new national formulary is historically the weakest one because of deductible resets. Alloush was explicit that the benefit "may take a little bit of time to really flow through." Adding noise: a “onetime cash outlay of $1.7 million” — Joseph Benesch, Chief Financial Officer · 2026-11-12 tied to a former-vendor dispute. Small in dollars, but it lands in the same quarter the market is trying to isolate clean operating leverage.

In terms of giving guidance, we're strongly considering it... we're probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance, and we'll see how quickly those wins come and how things stabilize.

Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-11-12
That "strongly considering" is familiar music. On the prior call the CFO insisted “I expect to see the percentage of revenue from SG&A pretty consistent” — Joseph Benesch, Chief Financial Officer · 2026-08-12, and back in November 2025 management was promising “some significant gains and less reliance on the co-pay program” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2025-11-12. The co-pay program is still the swing factor. Guidance remains deferred — another quarter of the can being kicked toward "first half of next year."

What the tape and the balance sheet say

This is the strangest part of the story. The operations are inflecting; the equity is not. FBIO has fallen 35.8% over roughly 65 trading days, from a $2.93 peak in mid-August to the low end of its range, on a market cap under $70 million. A fresh, constructive report into a drawdown of that magnitude is a setup — either the market is discounting something management isn't saying, or it simply hasn't repriced a company this small. The fundamentals hint at the second possibility. Revenue of $19 million came in with a visible sequential step up, and the balance sheet has transformed: effective net cash stands near $158 million, up more than fivefold year over year — a figure that dwarfs the entire market capitalization. Liabilities to assets have compressed to roughly 35%, down from a peak of 106%. This is not a distressed balance sheet. The cost side tells its own story. Research and development has collapsed to under $1 million from a peak of $36 million, while SG&A has climbed to roughly $22 million as the launch is funded. Free cash flow of negative $62 million is the counterweight — the EBITDA positivity is real but the cash line hasn't yet followed.

The verdict

What changed this quarter is concrete: Emrosi crossed nine million in quarterly net sales, delivered a second positive-EBITDA quarter, and locked a 25-million-life formulary that converts coupon-funded scripts into actual money starting January. That is the difference between a launch and a business. What did not change: guidance is still deferred, the market access team still controls the volume cadence through copay and formulary timing, and October came in soft enough that management had to explain the mechanics of a dip. For a stock down more than a third into the print with cash on the balance sheet exceeding the enterprise, the setup is asymmetric — but only if the formulary win actually flows through gross-to-net before the patience runs out.